New hope for rare tumor disorder: belzutifan trial launches
NCT ID NCT07167329
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 32 times
Summary
This study looks at how well the drug belzutifan works for people with von Hippel-Lindau (VHL) syndrome, a genetic condition that causes tumors. About 100 participants will take belzutifan and be monitored for up to 2 years to see if their tumors shrink and how long the effects last. The goal is to control the disease, not cure it, and researchers will also track side effects like anemia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA/PARAGANGLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AC Camargo Cancer Center
RECRUITINGSão Paulo, São Paulo, 01509900, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.